CTLA4 and cancer: Surprisingly, replacement of Bifidobacterium pseudolongum by inosine, a metabolite produced by this bacterium, in combination with anti-CTLA4 and CpG (a common immunostimulatory anti-cancer compound) led to similar results in this cancer model (Mager et al., 2020) (Figure 1K).